We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone [Corrigendum].
- Authors
Price, David B; Henley, William; Cançado, José Eduardo Delfini; Fabbri, Leonardo M; Kerstjens, Huib AM; Papi, Alberto; Roche, Nicolas; Şen, Elif; Singh, Dave; Vogelmeier, Claus F; Barille, Sara; Nudo, Elena; Carter, Victoria; Skinner, Derek; Vella, Rebecca; Georges, George
- Abstract
Introduction section, the paragraph should be corrected from " ...Collectively, there is a requirement for a real- world study comparing the use of extrafine particle fixed dose combination beclometasone dipropionate (ef-FDC-BDP; with a MMAD of 1.1μm in FOSTER® and TRIMBOW® NEXTHALER® DPIs and 1.3μm in FOSTER® pMDI) with other ICSs, such as fine particle fluticasone (fp-FDC-F; with a MMAD of 3.9μm and 3.2μm for propionate (SERETIDE® DISKUS®) and furoate (RELVAR® ELLIPTA®) esters respectively).21–23 to " ...Collectively, there is a requirement for a real-world study comparing the use of extrafine particle fixed dose combination beclometasone dipropionate (ef-FDC-BDP; with a MMAD of 1.1µm in TRIMBOW® pMDI and 1.3µm in FOSTER® pMDI) with other ICSs, such as fine particle fluticasone (fp-FDC-F; with a MMAD of 3.9µm and 3.2µm for propionate (SERETIDE® DISKUS®) and furoate (RELVAR® ELLIPTA®) esters respectively).21-23 The authors apologize for this error and advise they do not affect the results of the paper. Read the original article
- Publication
International Journal of COPD, 2022, Vol 17, p489
- ISSN
1176-9106
- Publication type
Article
- DOI
10.2147/COPD.S363875